Johanna Joyce: We explore the brain metastasis niche

Johanna Joyce shared a post on X:

“Niche-labeling strategies can be incredibly informative for investigating different types of cellular communication in vivo – including for the tumor microenvironment..

In this new paper, we explore the brain metastasis niche..

We highlight some considerations when using this approach in established brain metastases, including avid uptake of the niche label by CD206+ brain macrophages..

The mCherry protein is retained in these cells, and can be transferred independent of requiring the sLP portion..

These are some points to be aware of when using fluorescent proteins like mCherry for labeling in the brain..

This study was led by a v talented postdoc in our lab, Matteo Massara.

Thanks also to Bastien Dolfi, Vlad Wischnewski, Emma Nolan for their experimental support.

And with our great appreciation to Ilaria Malanchi and Werner Held for invaluable advice, and providing the labeling constructs.

Finally, our thanks for funding Swiss National Science Foundation, Fondazione AIRC per la ricerca sul cancro, The Breast Cancer Research Foundation, Ludwig Cancer, Université de Lausanne, Charlie Teo Foundation, CRUK Research, Wellcome, ERC Research.”

Read further.
Source: Johanna Joyce/X

Johanna Joyce is a Professor at the University of Lausanne, Switzerland, and Full Member of the international Ludwig Institute for Cancer Research. Prior to relocating her lab to Switzerland in 2016, she was a Full Member at Memorial Sloan Kettering Cancer Center and a Full Professor at Weill Cornell Medical School in New York.

Johanna has been recognized for her contributions to cancer research through a series of awards including the Robert Bing Prize, Cloetta Prize, Metastasis Research Society Innovation Award, Swiss Bridge Award, American Cancer Society Scholar Award, Rita Allen Foundation Award, V Foundation Award, Sidney Kimmel Foundation Award, Fidler Innovation in Research Award, among many others.

In 2017, she was elected as a Member of EMBO and a Fellow of the European Academy of Cancer Sciences, and in 2020 she was elected to the Women in Cancer Research Council of the AACR. Johanna currently serves on the advisory boards of the CRUK Cambridge Institute and Cancer Center, Cambridge, UK; the IRB Institute, Barcelona, Spain; the Robert Bosch Center for Tumor Diseases, Stuttgart, Germany; the Institute for Research in Biomedicine, Bellinzona, Switzerland; and on the editorial boards of Science, Cancer Cell, Cancer Discovery, The Journal of Experimental Medicine, and Trends in Cancer.